Clinical Trials

  1. Pancreatic Cancer Prevention Program Registry and Tissue Bank for High-Risk Individuals
    • The backbone of the Muzzi Mirza Pancreatic Cancer Prevention & Genetics Program, this registry combines deidentified blood and tissue samples with epidemiologic, clinical, and family history data to establish an infrastructure that will allow future clinical, basic, and translational research.
  2. Secretin-Stimulated MRCP as an Early Screening Modality for Pancreatic Ductal Abnormalities in Patients at High Risk for Pancreatic Adenocarcinoma
    • Secretin is a naturally produced hormone that stimulates the pancreas to release pancreatic juices. A secretin-stimulated MRCP may enable better visualization of abnormalities in the pancreatic ducts, where most pancreatic cancers are thought to originate.
  3. Secretin-Stimulation for the Evaluation of Pancreatic Endocrine and Exocrine Function following Surgical Resection for Pancreatic Adenocarcinoma
    • An attempt to understand endocrine and exocrine function in post-operative patients through a non-invasive technique in order to better predict which patients may develop glucose intolerance or diabetes after surgery
  4. Molecular Genetics (BRCA1, BRCA2) and Epidemiology of Pancreatic Cancer in Ashkenazi Jewish Patients
    • Up to 25% of pancreatic cancers have an inherited component. Several gene abnormalities and inherited cancer syndromes have been shown to increase the risk of developing pancreas cancer, including the breast ovary cancer syndrome (BRCA mutations). This study aims to determine the frequency of the three most common BRCA1 and BRCA2 mutations in Ashkenazi Jewish pancreas cancer patients. We also hope to look for other genetic mutations which may affect pancreas cancer.

If you are interested in enrolling a patient in any one of our open clinical trials, would like a brochure, or more information, please call our Program Coordinator, Ashley Dikos at 212.305.9337